Dan Feng
Medical Oncology · New York, NYNPI 1619408374
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,500 of the $13,960 with a category attached, or 89.5%. AstraZeneca accounts for 64.2% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $10,416, more than ten times the $267 reported in 2023.
Across 17 payments — averaging $821.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$9K
- Eisai Inc.$4K
- Biontech SE$153
- Intera Oncology, Inc$147
- Immunocore Limited$142
- Array Biopharma Inc$139
- plus $168 from 2 others
Across 38 payments — averaging $18,131 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$329K
- AstraZeneca$189K
- Alnylam Pharmaceuticals Inc.$116K
- Beone Medicines Ltd.$36K
- Beigene USA, Inc.$13K
- Biontech SE$6K
- plus $209 from 1 others
What the payments were for
- Consulting fees$12,50090%
- Food & beverage$1,46010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $8,966 |
| Eisai Inc. | 3 | $4,246 |
| Biontech SE | 1 | $153 |
| Intera Oncology, Inc | 1 | $147 |
| Immunocore Limited | 1 | $142 |
| Array Biopharma Inc | 1 | $139 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Merck | 2 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,960 in reported general payments places this provider in the 60th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 21 | $360 |
| Prochlorperazine Maleate | 11 | $165 |
| Potassium Chloride | 12 | $148 |
| Furosemide | 16 | $38 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in New York
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Ghassan Abou-AlfaNew York$825K
- Miguel PeralesNew York$769K
- Komal JhaveriNew York$642K
- Joshua BrodyNew York$492K
- Aiwu HeNew York$445K
- Raajit RampalNew York$418K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.